CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
Liraglutide +1 moredrug
Likely dose
Liraglutide 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02953665
NCT02953665Phase 2Completed
CompareCT.gov

A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease

Cedars-Sinai Medical Center·interventional·Posted Nov 3, 2016·Updated Mar 7, 2024

In Brief

A Phase 2 clinical trial evaluating Liraglutide and Placebo for Parkinson Disease. Completed, enrolled 63 participants across 1 site.

Detailed Summary

The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesUnited States
CollaboratorsCure Parkinson's, Novo Nordisk A/S

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 3, 2016
Enrollment StartApr 3, 2017
Primary CompletionAug 3, 2022
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 9.7 years ago

Interventions

Liraglutidedrug

Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg

Placebodrug

Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg